A phase 2 study of encorafenib in combination with binimetinib for Chinese participants with BRAFV600E mutated metastatic non-small cell lung cancer: Results from the OCEAN II study

Study limitation reported by the research below: “The pivotal-part primary efficacy analysis covered the first 50 participants, while the ad hoc analysis included all 63; clinicians should note the unplanned nature of the larger analysis.”